1. Home
  2. WINT vs ATXG Comparison

WINT vs ATXG Comparison

Compare WINT & ATXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WINT
  • ATXG
  • Stock Information
  • Founded
  • WINT 1992
  • ATXG 2014
  • Country
  • WINT United States
  • ATXG China
  • Employees
  • WINT N/A
  • ATXG N/A
  • Industry
  • WINT Biotechnology: Biological Products (No Diagnostic Substances)
  • ATXG Professional Services
  • Sector
  • WINT Health Care
  • ATXG Consumer Discretionary
  • Exchange
  • WINT Nasdaq
  • ATXG Nasdaq
  • Market Cap
  • WINT 2.2M
  • ATXG 3.8M
  • IPO Year
  • WINT 1995
  • ATXG N/A
  • Fundamental
  • Price
  • WINT $0.14
  • ATXG $0.50
  • Analyst Decision
  • WINT Hold
  • ATXG
  • Analyst Count
  • WINT 1
  • ATXG 0
  • Target Price
  • WINT $350.00
  • ATXG N/A
  • AVG Volume (30 Days)
  • WINT 5.2M
  • ATXG 173.8K
  • Earning Date
  • WINT 08-26-2025
  • ATXG 08-14-2025
  • Dividend Yield
  • WINT N/A
  • ATXG N/A
  • EPS Growth
  • WINT N/A
  • ATXG N/A
  • EPS
  • WINT N/A
  • ATXG N/A
  • Revenue
  • WINT N/A
  • ATXG $4,310,835.00
  • Revenue This Year
  • WINT N/A
  • ATXG N/A
  • Revenue Next Year
  • WINT N/A
  • ATXG N/A
  • P/E Ratio
  • WINT N/A
  • ATXG N/A
  • Revenue Growth
  • WINT N/A
  • ATXG N/A
  • 52 Week Low
  • WINT $0.10
  • ATXG $0.36
  • 52 Week High
  • WINT $662.00
  • ATXG $1.86
  • Technical
  • Relative Strength Index (RSI)
  • WINT 24.01
  • ATXG 48.95
  • Support Level
  • WINT $0.45
  • ATXG $0.43
  • Resistance Level
  • WINT $0.51
  • ATXG $0.51
  • Average True Range (ATR)
  • WINT 0.08
  • ATXG 0.04
  • MACD
  • WINT -0.05
  • ATXG 0.01
  • Stochastic Oscillator
  • WINT 8.93
  • ATXG 77.05

About WINT Windtree Therapeutics Inc.

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

About ATXG Addentax Group Corp.

Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.

Share on Social Networks: